Skip to main content
. 2018 Jun 3;14(9):1054–1066. doi: 10.7150/ijbs.25349

Figure 3.

Figure 3

CCL2 suppressed apoptosis via attenuating PI3K/AKT-mTOR pathway. (a) The level of phosphorylated AKT (P-AKT), phosphorylated mTOR (P-mTOR) in different cells as indicated was determined by Western blotting. (b) The level of phosphorylated P-AKT and P-mTOR in SGC7901/DDP cells before and after CCL2 knockdown was determined by Western blotting. (c) The level of P-AKT and P-mTOR in SGC7901 cells incubated with or without recombinant CCL2 was determined by Western blotting. (d) The level of cleaved PARP1 induced by 1.2 μg/ml cisplatin in SGC7901 cells treated as indicated was determined by Western blotting. (e) The LC3 and SQSTM1 protein levels in SGC7901 cells and SGC7901/DDP cells before and after EBSS treatment were determined by Western blotting.